DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mqcrh7/bcell_chronic) has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AB Science SA
- AbbVie Inc.
- Advancell
- Amgen Inc.
- BioNovion B.V.
- Celgene Corporation
- Dynavax Technologies Corporation
- Eisai Co., Ltd.
- F. Hoffmann-La Roche Ltd.
- Formula Pharmaceuticals, Inc.
- iDD biotech SAS
- Immunomedics, Inc.
- Johnson & Johnson
- Juno Therapeutics Inc.
- Nippon Shinyaku Co., Ltd.
- Noxxon Pharma AG
- Ono Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- SBI Biotech Co., Ltd.
- TheraMAB LLC
- Vivia Biotech, S.L.
Drug Profiles
- 202-b
- AB-8779
- acadesine
- alemtuzumab biosimilar
- AMG-319
- bafetinib
- BION-1301
- Cell Therapy for Hematological Malignancies
- Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies
- Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies
- Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies
- Cell Therapy to Target CD16 for CLL and NHL
- Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia
- Cell Therapy to Target CD19 for Cancer
- Cell Therapy to Target CD19 for Oncology
- Cell Therapy to Target CD23 for B-Cell Chronic Lymphocytic Leukemia
- E-7449
- GNKS-356
- IDD-001
- IDD-002
- ilorasertib
- JNJ-64052781
- lenalidomide
- MAT-303
- olaptesed pegol
- ONO-4059
- REGN-1979
- SD-101
- TAB-08
- tocilizumab
- Vivia-009
For more information visit http://www.researchandmarkets.com/research/mqcrh7/bcell_chronic
